Oxford BioDynamics PLC Appointment of Chairman (4674I)
14 December 2020 - 6:00PM
UK Regulatory
TIDMOBD
RNS Number : 4674I
Oxford BioDynamics PLC
14 December 2020
14 December 2020
Oxford BioDynamics Plc
Board changes
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
developing personalised medicine tests based on 3D genomic
biomarkers, announces that Matthew Wakefield is joining the board
with immediate effect as Non-Executive Chairman. Matthew graduated
with a degree in law and has an MBA in finance. He has spent his 27
year career in the city working in senior positions in both the
fund management and investment banking industries.
Matthew started his career as a fund manager at Legal and
General Plc before moving into broking at Nomura Holdings, Inc. He
joined Collins Stewart Hawkpoint Limited ("Collins Stewart") in
1992 and was Head of Sales and a member of the management
committee. He left Collins Stewart in 2004, after 12 years, to work
for two charities, The Besom Foundation and The 999 Club. In 2011
Matthew set up the broking partnership Baden Hill LLP, where
Matthew will remain as a partner and shareholder. Matthew has an
in-depth knowledge of the Company having been one of the company's
earliest external shareholders. Baden Hill LLP raised capital for
the company at the IPO in 2016 and Matthew has acted as an advisor
to the Company from the IPO to the current time. Matthew is
currently interested in 468,813 Ordinary Shares in the Company 0.5%
of the issued share capital.
The current Chairman and NED Dr Peter Pack has elected to step
down from the Board for personal reasons having moved back to
Germany.
Jon Burrows, CEO commented:
"The Board of Oxford BioDynamics would like to thank Peter for
his service and contribution to the Company. During this
unprecedented time, his input and guidance, both technically and
commercially, has been invaluable, and we wish him every success
for his future. The Directors look forward to working with Matthew
to continue the development of the Company as it moves into the
next stage of commercialisation and growth."
Matthew Wakefield, the new Chairman, said:
"I have been associated with the company for well over a decade
and I am convinced now more than ever of the considerable potential
in the EpiSwitch(TM) technology. I am looking forward to leading
the Board as Chairman and working with Jon and the team in this
next phase of the Company's growth."
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Alexandre Akoulitchev, CSO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Tel: +44 (0)20 7408 4090
Broker
Edward Mansfield / John More
Instinctif Partners Tel: +44 (0)20 3727 1000
Melanie Toyne-Sewell / Agnes Stephens OxfordBioDynamics@instinctif.com
/ Katie Duffell
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
3D genomic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re-positioning programs,
enabling the personalization of therapeutics for patients in the
context of challenging pricing environments where improved clinical
outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit our website, www.oxfordbiodynamics.com , or follow us
on Twitter or LinkedIn .
The following information is disclosed under AIM Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies:
Full Name Matthew Anthony Wakefield
Age 61
-------------------------------------
Current directorships Tortin Germany LLP
Baden Hill Corporate Member Ltd
Baden Hill LLP
Green Park Environmental LLP
Green Park Emissions Reductions LLP
-------------------------------------
Past directorships None noted
and partnerships
-------------------------------------
Matthew Wakefield has confirmed that there is no other
additional information to be disclosed under Schedule 2 (g) of the
AIM Rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUOAKRRNUUAAA
(END) Dow Jones Newswires
December 14, 2020 02:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024